Medtech dealmaking grinds almost to a halt
M&A moves are down, venture rounds few and IPOs nonexistent.
Biopharma buyouts bounce back
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
Lilly goes cellular for $34m
And conveniently, Celltrans blazes a trail for cell therapies in diabetes.
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Lilly gambles on Dice
Lilly follows others into the oral autoimmune space, not long after its leader questioned the future of small molecules.
Unpartnered assets: on the shelf or hidden treasure?
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
Novartis takes the helicopter view on Chinook
After Calliditas and Travere secure US approvals Novartis doubles down on a rare kidney disease, but what will the FTC say?